RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

- UK-based RQ Biotechnology Ltd (RQ Bio) launches with funding from licensing deal with AstraZeneca for RQ Bio's existing early stage monoclonal antibodies (mAbs) against SARS-CoV-2 with payments

Related Keywords

United Kingdom ,London ,City Of ,Mike Westby ,Gavin Screaton ,Kostenloser Wertpapierhandel ,Clare Terlouw ,Paul Kellam ,Astrazeneca ,Oxford University Innovation ,Linkedin ,University Of Oxford ,United Rq Biotechnology Ltd Bio ,Head Of The Medical Sciences Division ,Chief Commercial Officer ,Sanofi Executive ,Chief Executive Officer ,United Kingdom Based ,Centauri Therapeutics ,Pfizer Rd Executive ,Virus Genomics ,Imperial College London ,Vice President ,Infectious Diseases ,Kymab United Kingdom ,Professor Gavin Screaton ,Medical Sciences Division ,Lifearc Ventures ,Hugo Fry ,Launches ,Goal ,Ransform ,Treatment ,Prevention ,Viral ,Nfectious ,Diseases ,Through ,Ntibody ,Technologies ,